Abstract: Provided are methods for sequential radiotherapies, such as XRT. In some embodiments, a higher dosage of an XRT may first be administered to a subject, optionally in combination with an immunotherapy, and subsequently a lower dosage XRT is administered to the subject to treat a cancer. Separating the dosage and intensity of the radiotherapies can be used to achieve improved therapeutic responses, such as improved anti-cancer responses, survival times, and/or abscopal effects.

Abstract: Provided are methods for sequential radiotherapies, such as XRT. In some embodiments, a higher dosage of an XRT may first be administered to a subject, optionally in combination with an immunotherapy, and subsequently a lower dosage XRT is administered to the subject to treat a cancer. Separating the dosage and intensity of the radiotherapies can be used to achieve improved therapeutic responses, such as improved anti-cancer responses, survival times, and/or abscopal effects.

Abstract: Provided are methods for sequential radiotherapies, such as XRT. In some embodiments, a higher dosage of an XRT may first be administered to a subject, optionally in combination with an immunotherapy, and subsequently a lower dosage XRT is administered to the subject to treat a cancer. Separating the dosage and intensity of the radiotherapies can be used to achieve improved therapeutic responses, such as improved anti-cancer responses, survival times, and/or abscopal effects.

Abstract: Provided herein are methods of using BMP7 levels as a marker for the selection of patients, such as non-small cell lung cancer patients, who will clinically respond to combination therapy comprising a BMP7 inhibitor and an immune checkpoint therapy, such as an anti-PD1 therapy and/or an anti-CTLA-4 therapy. Also provided are methods of treating the selected patients with a combination of a BMP7 inhibitor and an immune checkpoint therapy.

Abstract: A virtual reality headset incorporating gradient refractive index (GRIN) lenses within the optical blocks thereof. Optical blocks of varying size and position are used. GRIN lenses are fabricated to fit within the optical block and are shaped to possess desired application-specific characteristics such as having one or more diffractive surfaces.

Abstract: A system includes a knowledgebase for inferring relationships between biological categories, such as patient conditions, drugs, medical groups, genes, and trials. The system also includes a search engine for flexibly querying the knowledgebase to access relevant categories of results, such as drugs and ongoing clinical trials. The system may be a cloud-based system.

Abstract: A virtual reality headset incorporating gradient refractive index (GRIN) lenses within the optical blocks thereof. Optical blocks of varying size and position are used. GRIN lenses are fabricated to fit within the optical block and are shaped to possess desired application-specific characteristics such as having one or more diffractive surfaces.

Abstract: Disclosed herein are systems, methods, and machine readable media for implementing a knowledgebase for inferring relationships between biological categories such as patient conditions, drugs, medical groups, genes, and trials, and for flexibly querying that system to access relevant categories of results, such as drugs and ongoing clinical trials. The system may be a cloud-based system.

Abstract: Protein kinase inhibitors are disclosed having utility in the treatment of protein kinase-mediated diseases and conditions, such as cancer. The compounds of this invention have the following structure: including steroisomers, prodrugs and pharmaceutically acceptable salts thereof, wherein A is a ring moiety selected from: and wherein R1, R2, R3, X, Z, L1, Cycl1, L2 and Cycl2 are as defined herein. Also disclosed are compositions containing a compound of this invention, as well as methods relating to the use thereof.

Abstract: Protein kinase inhibitors are disclosed having utility in the treatment of protein kinase-mediated diseases and conditions, such as cancer. The compounds of this invention have the following structure: including steroisomers, prodrugs and pharmaceutically acceptable salts thereof, wherein A is a ring moiety selected from: and wherein R1, R2, R3, X, Z, L1, Cycl1, L2 and Cycl2 are as defined herein. Also disclosed are compositions containing a compound of this invention, as well as methods relating to the use thereof.

Abstract: Protein kinase inhibitors are disclosed having utility in the treatment of protein kinase-mediated diseases and conditions, such as cancer. The compounds of this invention have the following structure: including steroisomers, prodrugs and pharmaceutically acceptable salts thereof, wherein A is a ring moiety selected from: and wherein R1, R2, R3, X, Z, L1, Cycl1, L2 and Cycl2 are as defined herein. Also disclosed are compositions containing a compound of this invention, as well as methods relating to the use thereof.

Abstract: Protein kinase inhibitors are disclosed having utility in the treatment of protein kinase-mediated diseases and conditions, such as cancer. The compounds of this invention have the following structure: including steroisomers, prodrugs and pharmaceutically acceptable salts thereof, wherein A is a ring moiety selected from: and wherein R1, R2, R3, X, Z, L1, Cycl1, L2 and Cycl2 are as defined herein. Also disclosed are compositions containing a compound of this invention, as well as methods relating to the use thereof.

Abstract: A modular mold system includes a hot half and a cold half. The hot half has a heated distributor assembly to receive molding material from an injection molding machine. The distributor assembly has a forward side that is opposite a side of the distributor assembly that faces the injection molding machine. A plurality of heated multi-nozzle units may also be provided. Each multi-nozzle unit has a manifold and a plurality of forward-extending nozzles. Each multi-nozzle unit is individually forwardly removably fastened to the forward side of the distributor assembly and removable from the distributor assembly while the distributor assembly is fastened to the first platen. The cold half includes a mounting plate and a plurality of cold-side units associated with the multi-nozzle units. Each cold-side unit is removably fastened to the mounting plate and engagable with one of the multi-nozzle units to define the one or more mold cavities.

Abstract: A modular mold system includes a hot half and a cold half. The hot half has a heated distributor assembly to receive molding material from an injection molding machine. The distributor assembly has a forward side that is opposite a side of the distributor assembly that faces the injection molding machine. A plurality of heated multi-nozzle units may also be provided. Each multi-nozzle unit has a manifold and a plurality of forward-extending nozzles. Each multi-nozzle unit is individually forwardly removably fastened to the forward side of the distributor assembly and removable from the distributor assembly while the distributor assembly is fastened to the first platen. The cold half includes a mounting plate and a plurality of cold-side units associated with the multi-nozzle units. Each cold-side unit is removably fastened to the mounting plate and engagable with one of the multi-nozzle units to define the one or more mold cavities.

Abstract: Protein kinase inhibitors are disclosed having utility in the treatment of protein kinase-mediated diseases and conditions, such as cancer. The compounds of this invention have the following structure: including steroisomers, prodrugs and pharmaceutically acceptable salts thereof, wherein A is a ring moiety selected from: and wherein R1, R2, R3, X, Z, L1, Cycl1, L2 and Cycl2 are as defined herein. Also disclosed are compositions containing a compound of this invention, as well as methods relating to the use thereof.

Abstract: Protein kinase inhibitors are disclosed having utility in the treatment of protein kinase-mediated diseases and conditions, such as cancer. The compounds of this invention have the following structure: including steroisomers, prodrugs and pharmaceutically acceptable salts thereof, wherein A is a ring moiety selected from: and wherein R1, R2, R3, X, Z, L1, Cycl1, L2 and Cycl2 are as defined herein. Also disclosed are compositions containing a compound of this invention, as well as methods relating to the use thereof.

Abstract: Protein kinase inhibitors are disclosed having utility in the treatment of protein kinase-mediated diseases and conditions, such as cancer. The compounds of this invention have the following structure: including steroisomers, prodrugs and pharmaceutically acceptable salts thereof, wherein A is a ring moiety selected from: and wherein R1, R2, R3, X, Z, L1, Cycl1, L2 and Cycl2 are as defined herein. Also disclosed are compositions containing a compound of this invention, as well as methods relating to the use thereof.

Abstract: A dry powder inhaler includes an actuator pivotably mounted on a base. Movement of the actuator from a first position to a second position drives the a dobber to open a blister. A dispersion engine sub-assembly has a blister hood positioned over a blister opening position. A powder pathway connects from the blister hood into a powder dispersion engine. Upon inhalation, air flow draws powder up and out of an opened blister, into the blister hood and to the powder dispersion engine. Movement of the actuator causes the dobber to shear open a blister and also to press the blister hood down over the blister. This increases air flows up and around the open blister, carrying the pharmaceutical powder up and out of the blister and into the dispersion engine.